Back to top
more

Veeva Systems (VEEV)

(Delayed Data from NYSE)

$282.13 USD

282.13
846,361

+2.37 (0.85%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $282.35 +0.22 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 244)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Benjamin Rains headshot

3 Tech Stocks for Growth Investors to Buy Right Now

by Benjamin Rains

Let's check out three tech stocks that came through our screen today that growth investors might want to consider at the moment...

Zacks Equity Research

Is Veeva Systems (VEEV) Outperforming Other Computer and Technology Stocks This Year?

by Zacks Equity Research

Is (VEEV) Outperforming Other Computer and Technology Stocks This Year?

Zacks Equity Research

The Zacks Analyst Blog Highlights: Veeva Systems, Cloudera, Facebook, Amazon and Alibaba

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Veeva Systems, Cloudera, Facebook, Amazon and Alibaba

Benjamin Rains headshot

3 Cloud Stocks to Buy Right Now

by Benjamin Rains

Check out these three Zacks buy-ranked cloud stocks to consider right now.

Kevin Cook headshot

2 Software IPOs from 2018 To Buy Now

by Kevin Cook

Software will continue to eat the world as productivity apps justify valuations in the clouds.

Sweta Jaiswal, FRM headshot

Healthcare's Near-Term Prospects Bright: 3 ETFs in Focus

by Sweta Jaiswal, FRM

The healthcare space might have seen a sluggish year so far. But its valuation and near-term prospects make it a good space for investments right now.

Zacks Equity Research

Is Veeva Systems (VEEV) Outperforming Other Computer and Technology Stocks This Year?

by Zacks Equity Research

Is (VEEV) Outperforming Other Computer and Technology Stocks This Year?

Zacks Equity Research

Veeva Systems (VEEV) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Veeva Systems (VEEV) closed the most recent trading day at $130.95, moving +1.75% from the previous trading session.

Zacks Equity Research

Why Veeva Systems (VEEV) is an Attractive Pick Right Now?

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio is likely to provide it with a competitive edge in the MedTech space.

Zacks Equity Research

Veeva (VEEV) Up 6.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Veeva (VEEV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Varian Medical (VAR) Collaborates With Korea-Based Hospital

by Zacks Equity Research

Varian Medical (VAR) has seen notable developments in Asia of late.

Zacks Equity Research

Zimmer Biomet's FDA 510(k) Nod Widens Robotic Offerings

by Zacks Equity Research

With the FDA nod, Zimmer Biomet (ZBH) attains the status of being the first company to boast the 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform globally.

Zacks Equity Research

Why Veeva Systems (VEEV) Could Be Positioned for a Surge

by Zacks Equity Research

Veeva Systems (VEEV) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Zacks Equity Research

Here's Why You Should Invest in Genomic Health (GHDX) Now

by Zacks Equity Research

Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now making considerable expansion in the international arena.

Zacks Equity Research

Abbott's New CE Mark to Boost Core Laboratory Diagnostics Arm

by Zacks Equity Research

Abbott's (ABT) Alinity m diagnostics system and assays will provide increased flexibility and time efficiency while catering to the rising demand for infectious disease testing.

Zacks Equity Research

AMN Healthcare Down on Soft Locum Tenens Business, Dull View

by Zacks Equity Research

Dependence on third parties is detrimental for AMN Healthcare (AMN).

Zacks Equity Research

Has Veeva Systems (VEEV) Outpaced Other Computer and Technology Stocks This Year?

by Zacks Equity Research

Is (VEEV) Outperforming Other Computer and Technology Stocks This Year?

Zacks Equity Research

Fresenius Medical's New Hemodialysis Software Gets FDA Nod

by Zacks Equity Research

Fresenius Medical (FMS) offers a wide range of HD and PD dialysis products.

Zacks Equity Research

National Vision (EYE) Rides on Positive Comps Amid Cost Woes

by Zacks Equity Research

National Vision (EYE) has been witnessing positive comps owing to increased customer transaction over the last 68 sequential quarters.

Zacks Equity Research

STERIS (STE) Margin Pressure Hurts, Strategic Growth High

by Zacks Equity Research

Mounting operating expenses are weighing on the bottom line of STERIS (STE).

Zacks Equity Research

TeleFlex Announces Multiple Positive Outcomes on UroLift

by Zacks Equity Research

A study by TeleFlex (TFX) sheds light on the real-world retrospective data on 30 men suffering urinary retention treated with the UroLift System.

Zacks Equity Research

Here's Why You Should Hold on to Cerner (CERN) Stock for Now

by Zacks Equity Research

Recently, Cerner (CERN) expanded its reach in the Alabama rural health care market through a new collaboration.

Zacks Equity Research

Computer Systems & Jasper General Tie Up to Boost EHR Service

by Zacks Equity Research

Computer Systems (CPSI) sees a series of developments in the EHR platform.

Zacks Equity Research

Abbott (ABT) Gains Ground on Solid EPD and Diabetes Arms

by Zacks Equity Research

Abbott's (ABT) EPD business operates in emerging geographies like India, Russia, China and Latin America.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Amazon, Microsoft, Twilio, Veeva and Equinix

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Amazon, Microsoft, Twilio, Veeva and Equinix